Skip Navigation

This Article
Right arrow Full Text Freely available
Right arrow FREE Full Text (PDF) Freely available
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in ISI Web of Science
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrow Search for citing articles in:
ISI Web of Science (17)
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by Schwab, J.
Right arrow Articles by Illges, H.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Schwab, J.
Right arrow Articles by Illges, H.
Social Bookmarking
 Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

International Immunology, Vol. 13, No. 5, 705-710, May 2001
© 2001 Japanese Society for Immunology

Regulation of CD21 expression by DNA methylation and histone deacetylation

Jörg Schwab1 and Harald Illges1,2

1 Immunology, Department of Biology, Faculty of Sciences, University of Konstanz, M662, 78457 Konstanz, Germany
2 Biotechnologie Institut Thurgau, Konstanzerstrasse 19, 8274 Tägerwilen, Switzerland

Correspondence to: H. Illges, Immunology, Department of Biology, Faculty of Sciences, University of Konstanz, M662, 78457 Konstanz, Germany

The complement receptor II (CD21) serves as a receptor for the complement component C3d of immune complexes on B lymphocytes. Expression of the CD21 gene is tightly regulated during B lymphocyte differentiation. Only mature B lymphocytes, but not pro-, pre- or plasma B lymphocytes, express CD21. There is evidence that cell type-specific expression is mediated by a silencer element located in the first intron. The CD21 promoter region contains a CpG island adjacent to the ATG start codon. We have analyzed the methylation status of this CpG island in B lymphoid cell lines representing the various differentiation stages of B lymphocyte development and primary lymphocytes. We found that the pro-, pre- and intermediate B lymphocytes contain a methylated CpG island and do not express CD21, whereas CD21-expressing mature B lymphocytes, plasma B lymphocytes and non-lymphoid cells carry a demethylated CD21 CpG island. To analyze whether the lack of CD21 expression in early B lymphocytes is due to inhibition by CpG methylation we have used 5-aza-2'-deoxycytidine to inhibit DNA methyltransferase activity. Treatment of pro-B lymphocytes with the drug resulted in expression of CD21. We have also applied Trichostatin A (TSA), an inhibitor of histone deacetylation, to determine whether the state of histone deacetylation affects the expression of CD21. We found that TSA induces expression of CD21 in early B lymphocytes. Thus CD21 expression is controlled by both methylation of the CD21 CpG island and chromatin modification through histone deacetylation in early B lymphocyte development.

Keywords: B lymphocyte, chromatin, complement receptor II, CR2, differentiation

Transmitting editor: A. Radbruch


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?


This article has been cited by other articles:


Home page
J. Immunol.Home page
I. Debnath, K. M. Roundy, J. J. Weis, and J. H. Weis
Defining In Vivo Transcription Factor Complexes of the Murine CD21 and CD23 Genes
J. Immunol., June 1, 2007; 178(11): 7139 - 7150.
[Abstract] [Full Text] [PDF]


Home page
J. Cell Sci.Home page
A. Aichem, M. Masilamani, and H. Illges
Redox regulation of CD21 shedding involves signaling via PKC and indicates the formation of a juxtamembrane stalk
J. Cell Sci., July 15, 2006; 119(14): 2892 - 2902.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
C. Gebhard, L. Schwarzfischer, T.-H. Pham, E. Schilling, M. Klug, R. Andreesen, and M. Rehli
Genome-wide profiling of CpG methylation identifies novel targets of aberrant hypermethylation in myeloid leukemia.
Cancer Res., June 15, 2006; 66(12): 6118 - 6128.
[Abstract] [Full Text] [PDF]


Home page
Int ImmunolHome page
H.-g. Hu, H. Illges, C. Gruss, and R. Knippers
Distribution of the chromatin protein DEK distinguishes active and inactive CD21/CR2 gene in pre- and mature B lymphocytes
Int. Immunol., June 1, 2005; 17(6): 789 - 796.
[Abstract] [Full Text] [PDF]


Home page
Cancer Res.Home page
N. Sato, A. Maitra, N. Fukushima, N. T. van Heek, H. Matsubayashi, C. A. Iacobuzio-Donahue, C. Rosty, and M. Goggins
Frequent Hypomethylation of Multiple Genes Overexpressed in Pancreatic Ductal Adenocarcinoma
Cancer Res., July 15, 2003; 63(14): 4158 - 4166.
[Abstract] [Full Text] [PDF]


Home page
Cancer Epidemiol. Biomarkers Prev.Home page
K. Bhatia, A. K Siraj, A. Hussain, R. Bu, and M. I Gutierrez
The Tumor Suppressor Gene 14-3-3{sigma} Is Commonly Methylated in Normal and Malignant Lymphoid Cells
Cancer Epidemiol. Biomarkers Prev., February 1, 2003; 12(2): 165 - 169.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
R. P. Friday, S. L. Pietropaolo, J. Profozich, M. Trucco, and M. Pietropaolo
Alternative Core Promoters Regulate Tissue-specific Transcription from the Autoimmune Diabetes-related ICA1 (ICA69) Gene Locus
J. Biol. Chem., January 3, 2003; 278(2): 853 - 863.
[Abstract] [Full Text] [PDF]


Home page
J. Immunol.Home page
R. M. Thomas, K. Haleem, A. B. Siddique, W. J. Simmons, N. Sen, D.-J. Zhang, and V. K. Tsiagbe
Regulation of Mouse Mammary Tumor Virus env Transcriptional Activator Initiated Mammary Tumor Virus Superantigen Transcripts in Lymphomas of SJL/J Mice: Role of Ikaros, Demethylation, and Chromatin Structural Change in the Transcriptional Activation of Mammary Tumor Virus Superantigen
J. Immunol., January 1, 2003; 170(1): 218 - 227.
[Abstract] [Full Text] [PDF]


Home page
J. Biol. Chem.Home page
A. L. B. Cabral, K. S. Lee, and V. R. Martins
Regulation of the Cellular Prion Protein Gene Expression Depends on Chromatin Conformation
J. Biol. Chem., February 8, 2002; 277(7): 5675 - 5682.
[Abstract] [Full Text] [PDF]



Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.